Leukemia and Lymphoma Program News

Your child will be cared for by one of the most accomplished teams of childhood cancer experts in the world. We provide medical care, emotional counseling and much more.

How we serve you

Existing patients or family members

215-590-3025

New patients, referrals and second opinions

267-426-0762

New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response

Nov 28, 2022

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later

Jun 16, 2022

New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.

CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

May 23, 2022

CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.

CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care

Mar 18, 2022

More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.

CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma

Mar 10, 2022

In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).

CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion

Feb 2, 2022

A new study in Nature has documented the longest persistence of CAR T cell therapy to date.

Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Jan 4, 2022

Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.

CHOP Researchers Develop Humanized CAR T-Cell Therapy that Shows Potential for Patients with Relapsed B-ALL

Jun 28, 2021

The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.

Researchers Uncover How MN1 Overexpression Causes AML

May 10, 2021

CHOP researchers have found that MN1 overexpression leads to stabilization of the BAF complex, which leads to overproduction of progenitor and stem cells.

FDA Approves Drug for Rare Form of Pediatric Cancer

Jan 15, 2021

The FDA has approved a treatment that targets ALK mutations in relapsed, refractory ALK-positive anaplastic large cell lymphoma.

Find a research study

Innovation and your child

Find research studies